The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America [v1; ref status: indexed, http://f1000r.es/3ix]
Compared to a decade ago, nearly three times as many drugs for rare diseases are slated for development. This article addresses the market access issues associated with orphan drug status in Europe and the United States in contrast to the legislation in five Latin American (LA) countries that have m...
Main Authors: | Renée J.G. Arnold, Lida Bighash, Alejandro Bryón Nieto, Gabriela Tannus Branco de Araújo, Juan Gabriel Gay-Molina, Federico Augustovski |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2015-02-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | http://f1000research.com/articles/4-57/v1 |
Similar Items
-
Rare diseases and orphan drugs.
by: Aronson, J
Published: (2006) -
Orphan drugs and rare diseases /
by: Pryde, David C., editor, et al.
Published: (2014) -
Rare diseases and orphan drugs
by: Domenica Taruscio, et al.
Published: (2011-01-01) -
Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023-01-01) -
Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016-01-01)